Tag Archives: BMY stock research

25Q2 net revenue rose 0.6% to $12.3 billion, as a 17.9% gain in the growth portfolio more than offset a 14.1% decline in the legacy portfolio.  Among the individual medicines, sales gains in Eliquis, Breyanzi, Opdivo, Reblozyl and Camzyos were … Continue reading →

25Q1 net revenue decreased 5.6% to $11.2 billion, as declines in Eliquis and Revlimid were only partially offset by an increase in Opdivo.  BMY’s growth portfolio posted a 16.1% YOY revenue increase, the slowest in a year; while the legacy … Continue reading →

24Q4 net revenue rose 7.5% to $12.3 billion, with gains in Eliquis and the growth portfolio more than offsetting LOE-related declines in Revlimid, Pomalyst, Sprycel and Abraxane.  Growth portfolio net revenues rose 9.5% sequentially and 29% YOY.  Gross margin fell … Continue reading →